The purpose of the scientific research project utilizing CDI's iCell Cardiomyocytes in space is to validate the function of NASA's new bioculture system for automated cell culture on the ISS and to study human cardiac cell function in microgravity.
Developed and manufactured by CDI, iCell Cardiomyocytes are derived from human induced pluripotent stem cells (iPSCs) and recapitulate many of the salient features of native healthy and disease-related human cardiac function, including electrical activity, calcium cycling, contraction, as well as normal and pathological responses to environmental changes.
The bioculture system is a new research facility that will let scientists carry out long-term cell biology studies on a broad range of subjects and diverse cell and tissue types.
This new hardware will allow for real-time remote monitoring of cell cultures, and finer control over the conditions in which they grow.
CDI, a Fujifilm company, is a developer and supplier of human cells used in drug discovery, toxicity testing, and regenerative medicine applications.
Able to create iPSCs and differentiated tissue-specific cells from any individual, the company's inventoried iCell products and donor-specific MyCell Products are available in the quantity, quality, purity, and reproducibility required for drug and cell therapy development.
Tokyo, Japan-based Fujifilm Holdings Corp. a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies to a broad spectrum of industries, including healthcare, graphic systems optical devices, digital imaging, and document products.
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies
CirCode Biomed's IND application for HM2002 receives FDA clearance
CeleCor Therapeutics completes Phase 3 trial of new anti-platelet agent for heart attack
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
Ionis reports positive Phase 3 results for olezarsen in moderate hypertriglyceridemia
Nordic Bioscience launches new Endotrophin assay
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Otsuka's leukaemia drug ponatinib launched on Fangzhou platform
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Avacta Therapeutics reports positive Phase 1 data for lead candidate
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment